Novel drugs with complex design are becoming more common to treat difficult diseases.
This insight brief, authored by Michael Brown, Ph.D., Senior Director, Immunoanalytical Services and Barry Jones, Ph.D., Director, LC-MS Biologics and Biomarkers, provides an overview of the development of assays for these novel drugs including where the field may be moving in the future.
Complete the form below to access this insight brief
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Hybrid Assays for Protein Bioanalysis
Assays and Why Are They Essential for Protein Bioanalysis?
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
High Throughput ADME Testing
Minimizing turnaround time for ADME assays
ADME Services
Accelerating your drug discovery, preclinical and clinical programs with ADME services
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
Early Hit-to-Lead ADME Screening Bundle
Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery
High Throughput ADME Screening Services
Capabilities that accelerate preclinical studies
IND-Enabling Bundle of In Vitro Assays to Assess Drug-Drug Interaction Risk
DDI Fact Sheet
In vitro ADME, LC-MS/MS bioanalysis and metabolite identification service list
Services to support your In Vitro ADME development needs
